发明名称 Solvent cast film sustained release latanoprost implant
摘要 The present invention provides a sustained release latanoprost implant in the form of a thin film comprising latanoprost incorporated in a biodegradable polymer matrix. Preferably, said implant is an intraocular implant comprising a thin film comprising latanoprost incorporated in a biodegradable polymer matrix wherein said implant is configured as a disc or a rolled film that can be inserted into the eye and unrolls to provide a film having a high surface area to volume ratio.
申请公布号 US9161929(B2) 申请公布日期 2015.10.20
申请号 US201414220945 申请日期 2014.03.20
申请人 Allergan, Inc. 发明人 Ghebremeskel Alazar N.;Spada Lon T.
分类号 A61F2/00;A61K31/216;A61K9/00;A61K9/70;A61K31/5575;A61K47/34;A61F9/00 主分类号 A61F2/00
代理机构 代理人 Wine Laura L.;German Joel B.;Condino Debra D.
主权项 1. A method of treating open-angle glaucoma or ocular hypertension comprising (1) inserting into an eye of a patient in need of such treatment a rolled biodegradable film, wherein the film is rolled into a cylindrical shape, and wherein the insertion of the film is performed using a needle and syringe; (2) allowing the rolled film, once inserted into the eye, to unfurl to its original shape to thereby expose its entire surface to provide for drug diffusion out of the film and into the eye;thereby lowering the intraocular pressure of the eye;wherein the film consists of about 30% by weight latanoprost, about 35% by weight R208, which is an ester terminated poly(D,L-lactide) having an inherent viscosity of about 1.8-2.2 dl/g, and about 35% by weight RG755, which is an ester terminated poly(D,L-lactide-co-glycolide) having an inherent viscosity of about 0.50-0.70 dl/g and a D,L-lactide:glycolide ratio of about 75:25.
地址 Irvine CA US